JAC Advance Access originally published online on May 18, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(1):217-220; doi:10.1093/jac/dkh279
JAC vol.54 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience
1 Clinica Malattie Infettive, Università di Messina, Messina; 2 AILMI (Associazione Italiana per la Lotta contro le Malattie Infettive) ONLUS, Messina; 3 U.O. di Pediatria Infettivologica, A.O. Santobono-Pausilipon, Napoli; 4 Unità Operativa di Malattie Infettive, Istituto G. Gaslini, Genova; 5 Dipartimento Malattie Infettive, Policlinico Umberto I, Università La Sapienza Roma, Rome; 6 Istituto di Patologia Infettiva e Virologia, Università di Palermo, Palermo; 7 Laboratorio di Parassitologia, Istituto Superiore di Sanità, Rome; 8 Istituto di Malattie Infettive e Tropicali, Università di Milano, Milan, Italy
* Correspondence address. Clinica Malattie Infettive, Università di Messina, Via Consolare Valeria n. 1, 98125 Messina, Italy. Tel: +39-090-221-2033; Fax: +39-178-225-6846; Email: acascio{at}unime.it
Objectives: To evaluate in a retrospective analysis the efficacy and safety of a 6 day course of liposomal amphotericin B (L-AmB) in infantile cases of Mediterranean visceral leishmaniasis (VL) diagnosed over a 10 year period in Italy.
Patients and methods: Patients included were diagnosed as having VL consecutively admitted from December 1992 to December 2001 at four main referral children's hospitals in Italy and treated with six intravenous doses of 3 mg/kg L-AmB given on days 15 and 10 (a total dose of 18 mg/kg). Demographic data, nutritional status, underlying diseases, clinical and laboratory findings, and therapy outcome were considered.
Results: A total of 164 HIV-negative children (median age 1.6 years; range 4 months to 14 years) were enrolled. All patients were initially cured by the given treatment, and did not present adverse events related to drug infusion. Seven patients (4.3%) had a clinical and parasitological relapse 315 months after therapy. All relapses were successfully retreated with 3 mg/kg L-AmB for 10 consecutive days (a total dose of 30 mg/kg).
Conclusions: This study highlights the efficacy (>95%) and safety of the six dose L-AmB regimen and validates it as a first-line treatment for Mediterranean VL in children.
Keywords: Leishmania infantum , Italy , therapy